IL-12 Enhances the Antitumor Actions of Trastuzumab via NK Cell IFN-γ Production-Reference-Cited by-同舟云学术

IL-12 Enhances the Antitumor Actions of Trastuzumab via NK Cell IFN-γ Production

Published:2011-02-14 Issue:6 Volume:186 Page:3401-3409
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J.I.

Author:

Jaime-Ramirez Alena Cristina,Mundy-Bosse Bethany L.,Kondadasula SriVidya,Jones Natalie B.,Roda Julie M.,Mani Aruna,Parihar Robin,Karpa Volodymyr,Papenfuss Tracey L.,LaPerle Krista M.,Biller Elizabeth,Lehman Amy,Ray Chaudhury Abhik,Jarjoura David,Burry Richard W.,Carson William E.

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference38 articles.

1. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands.;Tzahar;Biochim. Biophys. Acta,1998

2. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.;Pinkas-Kramarski;EMBO J.,1996

3. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.;Baselga;J. Clin. Oncol.,1996

4. ERBB2 oncogene in human breast cancer and its clinical significance

5. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.;Ross;Oncologist,1998

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interleukin-12 in multimodal tumor therapies for induction of anti-tumor immunity;Discover Oncology;2024-05-16

2. Analysis of Changes in Plasma Cytokine Levels in Response to IL12 Therapy in Three Clinical Trials;Cancer Research Communications;2024-01-10

3. An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer;Cancer Control;2024-01

4. Combination of NK cell immunotherapy with chemotherapy and radiation enhances NK cell therapy and provides improved prognosis in cancer patients and in humanized BLT mouse model system;NK Cells in Cancer Immunotherapy: Successes and Challenges;2023

5. Patients with positive HER-2 amplification advanced gastroesophageal junction cancer achieved complete response with combined chemotherapy of AK104/cadonilimab (PD-1/CTLA-4 bispecific): A case report;Frontiers in Immunology;2022-12-08